Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
Identifieur interne : 005D97 ( Main/Exploration ); précédent : 005D96; suivant : 005D98Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
Auteurs : Baltazar Gomez-Mancilla [Canada, Suisse] ; René Boucher [Canada, Suisse] ; Céline Gagnon [Canada, Suisse] ; Thérèse Di Paolo [Canada, Suisse] ; Rudolf Markstein [Canada, Suisse] ; Bédard [Canada, Suisse]Source :
- Movement Disorders [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Antiparkinson Agents (administration & dosage), Bromocriptine, Bromocriptine (administration & dosage), CY 208–243, Corpus Striatum (drug effects), Corpus Striatum (pathology), D1 agonist, D2 agonist, Dopamine (metabolism), Dose-Response Relationship, Drug, Drug Therapy, Combination, Homovanillic Acid (metabolism), Indoles (administration & dosage), Locomotion (drug effects), MPTP‐treated monkey, Macaca fascicularis, Motor Skills (drug effects), Motor Skills (physiology), Neurologic Examination, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinson Disease, Secondary (pathology), Parkinsonism, Phenanthridines (administration & dosage), Psychomotor Performance (drug effects), Receptors, Dopamine (drug effects), Receptors, Dopamine (ultrastructure), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (ultrastructure).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Bromocriptine, Indoles, Phenanthridines.
- chemical , drug effects : Receptors, Dopamine, Receptors, Dopamine D1.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopamine, Homovanillic Acid.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Corpus Striatum, Locomotion, Motor Skills, Psychomotor Performance.
- drug therapy : Parkinson Disease, Secondary.
- pathology : Corpus Striatum, Parkinson Disease, Secondary.
- physiology : Motor Skills.
- chemical , ultrastructure : Receptors, Dopamine, Receptors, Dopamine D1.
- Animals, Dose-Response Relationship, Drug, Drug Therapy, Combination, Macaca fascicularis, Neurologic Examination.
Abstract
A group of four cynomolgus monkeys previously rendered parkinsonian by the toxin 1‐methyl‐4‐phenyl, 1, 2, 3, 6‐tetrahydropyridine (MPTP) were observed in locomotion cages equipped with photocells during four periods of 7 days during which they received saline or two doses of the D1 agonist CY 208–243. The larger dose of 0.5 mg/kg produced a singificant increase in locomotion in three of four animals. A second group of eight monkeys also previously rendered parkinsonian by MPTP and having received no other treatment were given a daily treatment of bromocriptine 1.66 mg/kg orally daily during 4 weeks. In four of the animals, after a week on bromocriptine alone, the D1 agonist CY 208–243 was added in increasing doses of 0.05, 0.1, and 0.5 mg/kg. The motor response as measured by locomotion, hand dexterity, and a disability score improved progressively at least in some of the animals on bromocriptine alone. The addition of CY 208–243 produced a more striking improvement of all three parameters, which appeared to be dose dependent. Biochemical analysis of the brain of these animals plus one control and one MPTP untreated monkey showed a<90% loss of dopamine in the striatum in six of the eight treated monkeys. Both D2 and D1 dopamine receptors were increased in density by denervation, but both treatments abolished this increase for the D2 receptors while increasing the affinity of the D1 receptors.
Url:
DOI: 10.1002/mds.870080205
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E32
- to stream Istex, to step Curation: 000E32
- to stream Istex, to step Checkpoint: 004064
- to stream PubMed, to step Corpus: 004C58
- to stream PubMed, to step Curation: 004C58
- to stream PubMed, to step Checkpoint: 004C61
- to stream Ncbi, to step Merge: 004A08
- to stream Ncbi, to step Curation: 004A08
- to stream Ncbi, to step Checkpoint: 004A08
- to stream Main, to step Merge: 009036
- to stream Main, to step Curation: 005D97
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors</title><author><name sortKey="Gomez Ancilla, Baltazar" sort="Gomez Ancilla, Baltazar" uniqKey="Gomez Ancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></author><author><name sortKey="Boucher, Rene" sort="Boucher, Rene" uniqKey="Boucher R" first="René" last="Boucher">René Boucher</name></author><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name></author><author><name sortKey="Bedard" sort="Bedard" uniqKey="Bedard" last="Bédard">Bédard</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EB6E52890278479C044B230DEB73C63DC1063917</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/mds.870080205</idno><idno type="url">https://api.istex.fr/document/EB6E52890278479C044B230DEB73C63DC1063917/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E32</idno><idno type="wicri:Area/Istex/Curation">000E32</idno><idno type="wicri:Area/Istex/Checkpoint">004064</idno><idno type="wicri:doubleKey">0885-3185:1993:Gomez Ancilla B:effect:of:adding</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8474480</idno><idno type="wicri:Area/PubMed/Corpus">004C58</idno><idno type="wicri:Area/PubMed/Curation">004C58</idno><idno type="wicri:Area/PubMed/Checkpoint">004C61</idno><idno type="wicri:Area/Ncbi/Merge">004A08</idno><idno type="wicri:Area/Ncbi/Curation">004A08</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A08</idno><idno type="wicri:doubleKey">0885-3185:1993:Gomez Mancilla B:effect:of:adding</idno><idno type="wicri:Area/Main/Merge">009036</idno><idno type="wicri:Area/Main/Curation">005D97</idno><idno type="wicri:Area/Main/Exploration">005D97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors</title><author><name sortKey="Gomez Ancilla, Baltazar" sort="Gomez Ancilla, Baltazar" uniqKey="Gomez Ancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Boucher, Rene" sort="Boucher, Rene" uniqKey="Boucher R" first="René" last="Boucher">René Boucher</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bedard" sort="Bedard" uniqKey="Bedard" last="Bédard">Bédard</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy and Department of Molecular Endocrinolgy, CHUL Research Center, Laval University Medical Center, Sainte‐Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hǒpital de l'Enfant‐Jésus, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research, Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993">1993</date><biblScope unit="vol">8</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="144">144</biblScope><biblScope unit="page" to="150">150</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">EB6E52890278479C044B230DEB73C63DC1063917</idno><idno type="DOI">10.1002/mds.870080205</idno><idno type="ArticleID">MDS870080205</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Bromocriptine</term><term>Bromocriptine (administration & dosage)</term><term>CY 208–243</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (pathology)</term><term>D1 agonist</term><term>D2 agonist</term><term>Dopamine (metabolism)</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Homovanillic Acid (metabolism)</term><term>Indoles (administration & dosage)</term><term>Locomotion (drug effects)</term><term>MPTP‐treated monkey</term><term>Macaca fascicularis</term><term>Motor Skills (drug effects)</term><term>Motor Skills (physiology)</term><term>Neurologic Examination</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Parkinsonism</term><term>Phenanthridines (administration & dosage)</term><term>Psychomotor Performance (drug effects)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (ultrastructure)</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (ultrastructure)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Indoles</term><term>Phenanthridines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Dopamine</term><term>Homovanillic Acid</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Locomotion</term><term>Motor Skills</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Skills</term></keywords><keywords scheme="MESH" type="chemical" qualifier="ultrastructure" xml:lang="en"><term>Receptors, Dopamine</term><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Macaca fascicularis</term><term>Neurologic Examination</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A group of four cynomolgus monkeys previously rendered parkinsonian by the toxin 1‐methyl‐4‐phenyl, 1, 2, 3, 6‐tetrahydropyridine (MPTP) were observed in locomotion cages equipped with photocells during four periods of 7 days during which they received saline or two doses of the D1 agonist CY 208–243. The larger dose of 0.5 mg/kg produced a singificant increase in locomotion in three of four animals. A second group of eight monkeys also previously rendered parkinsonian by MPTP and having received no other treatment were given a daily treatment of bromocriptine 1.66 mg/kg orally daily during 4 weeks. In four of the animals, after a week on bromocriptine alone, the D1 agonist CY 208–243 was added in increasing doses of 0.05, 0.1, and 0.5 mg/kg. The motor response as measured by locomotion, hand dexterity, and a disability score improved progressively at least in some of the animals on bromocriptine alone. The addition of CY 208–243 produced a more striking improvement of all three parameters, which appeared to be dose dependent. Biochemical analysis of the brain of these animals plus one control and one MPTP untreated monkey showed a<90% loss of dopamine in the striatum in six of the eight treated monkeys. Both D2 and D1 dopamine receptors were increased in density by denervation, but both treatments abolished this increase for the D2 receptors while increasing the affinity of the D1 receptors.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Suisse</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Gomez Ancilla, Baltazar" sort="Gomez Ancilla, Baltazar" uniqKey="Gomez Ancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></noRegion><name sortKey="Bedard" sort="Bedard" uniqKey="Bedard" last="Bédard">Bédard</name><name sortKey="Bedard" sort="Bedard" uniqKey="Bedard" last="Bédard">Bédard</name><name sortKey="Boucher, Rene" sort="Boucher, Rene" uniqKey="Boucher R" first="René" last="Boucher">René Boucher</name><name sortKey="Boucher, Rene" sort="Boucher, Rene" uniqKey="Boucher R" first="René" last="Boucher">René Boucher</name><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><name sortKey="Gomez Ancilla, Baltazar" sort="Gomez Ancilla, Baltazar" uniqKey="Gomez Ancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name></country><country name="Suisse"><noRegion><name sortKey="Gomez Ancilla, Baltazar" sort="Gomez Ancilla, Baltazar" uniqKey="Gomez Ancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></noRegion><name sortKey="Bedard" sort="Bedard" uniqKey="Bedard" last="Bédard">Bédard</name><name sortKey="Boucher, Rene" sort="Boucher, Rene" uniqKey="Boucher R" first="René" last="Boucher">René Boucher</name><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EB6E52890278479C044B230DEB73C63DC1063917
|texte= Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
}}
| This area was generated with Dilib version V0.6.23. |  |